β-L-2′-deoxynucleosides for the treatment of...

Details β-L-2′-deoxynucleosides for the treatment of... β-L-2′-deoxynucleosides for the treatment of...

2007-03-06

2007-03-06

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C042S043000, C042S050000, C042S051000

Reexamination Certificate

active

10662641

ABSTRACT:
It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

REFERENCES:
patent: 4916122 (1990-04-01), Chu et al.
patent: 4957924 (1990-09-01), Beauchamp
patent: 5190926 (1993-03-01), Chu et al.
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5256641 (1993-10-01), Yatvin et al.
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5463092 (1995-10-01), Hostetler et al.
patent: 5532246 (1996-07-01), Belleau et al.
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5543389 (1996-08-01), Yatvin et al.
patent: 5543390 (1996-08-01), Yatvin et al.
patent: 5543391 (1996-08-01), Yatvin et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5559101 (1996-09-01), Weis et al.
patent: 5565438 (1996-10-01), Chu et al.
patent: 5567688 (1996-10-01), Chu et al.
patent: 5587362 (1996-12-01), Chu et al.
patent: 5939402 (1999-08-01), Weis et al.
patent: 6025335 (2000-02-01), Weis et al.
patent: 6194391 (2001-02-01), Schinazi et al.
patent: 6242187 (2001-06-01), Capon et al.
patent: 6245749 (2001-06-01), Schinazi et al.
patent: 6265181 (2001-07-01), Dong et al.
patent: 6297222 (2001-10-01), von Borstel et al.
patent: 6395716 (2002-05-01), Gosselin et al.
patent: 6444652 (2002-09-01), Gosselin et al.
patent: 6566344 (2003-05-01), Gosselin et al.
patent: 6569837 (2003-05-01), Gosselin et al.
patent: 6855346 (2005-02-01), Wu
patent: 2003/0083306 (2003-05-01), Imbach et al.
patent: 0350287 (1990-01-01), None
patent: 0352248 (1990-01-01), None
patent: 0494119 (1992-07-01), None
patent: 0355131 (1996-09-01), None
patent: 06-293645 (1994-10-01), None
patent: WO 89/02733 (1989-04-01), None
patent: WO 89/03838 (1989-05-01), None
patent: WO 90/00555 (1990-01-01), None
patent: WO 91/16920 (1991-11-01), None
patent: WO 91/18914 (1991-12-01), None
patent: WO 91/19721 (1991-12-01), None
patent: WO 92/08727 (1992-05-01), None
patent: WO 92/15308 (1992-09-01), None
patent: WO 92/18517 (1992-10-01), None
patent: WO 93/00910 (1993-01-01), None
patent: WO 94/20523 (1994-09-01), None
patent: WO 94/26273 (1994-11-01), None
patent: WO 95/07086 (1995-03-01), None
patent: WO 96/11204 (1996-04-01), None
patent: WO 96/13512 (1996-05-01), None
patent: WO 96/15132 (1996-05-01), None
patent: WO 96/40164 (1996-12-01), None
patent: WO 00/09531 (2000-02-01), None
patent: WO 01/04358 (2001-01-01), None
patent: WO 01/96353 (2001-12-01), None
Delaney, et al., J. Hepatology, 2002, 36(suppl 1): 89, abstract 309.
Ahmed, S.N.S., et al., “Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B,”Hepatology, 32(5):1078-1088 (Nov. 2000).
Allen, M. I., et al., “Identification and characterization of mutations in hepatitis B virus resistant to lamivudine,”Hepatology27(6):1670-1677 (Jun. 1998).
Arner, E.S.J., et al., “Mammalian Deoxyribonicleoside Kinases,”Pharm. Ther., 67(2), 155-186 (1995).
Berk, A.J., et al., “A Genetically Distinct Tymidine Kinase in Mammalian Mitochondria,”J Biol Chem, 248(8):2722-2729 (1973).
Bestwick, R.K., et al., “Selective Expansion of Mitochondrial Nucleoside Triphosphate Pools in Antimetabolite-treated HeLa Cells,”J. Biol. Chem., 257(16):9300-9304 (1982).
Bloch, A., et al. “The Role Of The 5′-Hydroxyl Group Of Adenosine In Determining Substrate Specificity For Adenosine Deaminase,”J. Med. Chem., 10(5):908-12 (Sep. 1967).
Bridges, E.G., et al., “Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria,”J. Biol. Chem., 274(8):4620-4625 (Feb. 19, 1999).
Bridges, E.G., et al., “Identification of a novel mitochondrial dNTP carrier and its interaction with anti-HIV nucleoside analogs,”Proc. Am. Assoc. Cancer Res., 38:62, Abstract 414 (Mar. 1997).
Bridges, E.G., et al., “Inhibition of Mammalian DNA Polymerase-Associated 3′ to 5′ Exonuclease Activity by 5′-Monophosphates of 3′-Azido-3′-Deoxythymine and 3′-Amino-3′-Deoxythymidine,”Biochemical Pharmacology, 45(8):1571-1576 (1993).
Bryant, M.L., et al., “Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection,”Antimicrobial Agents and Chemotherapy, 45(1):229-235 (Jan. 2001).
Chang, C.N., et al., “Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (-)-2′,3′-thiacytidine in the Inhibition of Hepatitis B Virus Replication,”Journal of Biological Chemistry, 267(20):13938-13942 (Jul. 15, 1992).
Chang, C.-N., et al., “Biochemical Pharmacology of (+)- and (-)-2′,3′-Dideoxy-3′-thiacytidine as Anti-hepatitis B Virus Agents,”J Biol Chem, 267(31), 22414-22420 (Nov. 5, 1992).
Chariot, P., et al., “Zidovudine-induced mitochondrial disorder with massive liver steatosis myopathy, lactic acidosis, and mitochondrial DNA depletion,”J. Hepatology, 30:156-160 (1999).
Chayama, K., et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy,Hepatology27(6):1711-1716 (Jun. 1998).
Chen, M.S., et al., “Characterization of Pyrimidine Deoxyribonucleoside Kinase (Thymidine Kinase) and Thymidylate Kinase as a Multifunctional Enzyme in Cells Transformed by Herpes Simplex Virus Type 1 and in Cells Infected with Mutant Strains of Herpes Simplex Virus,”J Virol., 30(3):942-945 (Jun. 1979).
Chen, C.-H., et al., “Delayed Cytotoxicity and Selective Loss of Mitochondrial DNA in Cells Treated with the Anti-human Immunodeficiency Virus Compound 2′,3′-Dideoxycytidine,”J. Biol. Chem., 264(20):11934-11937 (Jul. 15, 1989).
Chen, C.-H., et al., “The Role of Cytoplasmic Deoxycytidine Kinase in the Mitochondrial Effects of the Anti-human Immunodeficiency Virus Compound 2′,3′-Dideoxycytine,”J. Biol. Chem., 267(5):2856-2859 (Feb. 15, 1992).
Cui, L., et al., “Effect of Nucleoside Analogs on Neurite Regeneration and Mitochondrial DNA Synthesis in PC-12 Cells,”J. of Pharmacology and Experimental Therapeutics, 280(3):1228-1234 (1997).
Das et al. “Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC),”Journal of Virology, 75(10):4771-4779 (May 2001).
Davis, A.F., et al., “In Situ Localization of Mitochondrial DNA Replication in Intact Mammalian Cells,”J Cell Biol, 135(4), 883-893 (Nov. 1996).
Davisson, V.J., et al., “Synthesis of Nucleotide 5′-Diphosphates from 5′-O-Tosyl Nucleosides,”J. Org. Chem., 52(9):1794-1801 (1987).
Delaney, “Cross-Resistance Testing of Antihepadnaviral Compounds using Novel Recombinant Baculoviruses which Encode Drug-Resistant Strains of Hepatitis B Virus,”Antimicrobial Agents and Chemotherapy, 45(6):1705-1713 (Jun. 2001).
Delaney, W.E., Huiling Y, Westland CE, et al. “In vitrocross resistance testing of adefovir, entecavir, and β-L-thymidine (L-DT) against drug-resistant strains of HBV,”Hepatology, 34(No. 4, Pt 2):628A, abstract #1825 (2001).
Doong, S.-L., et al., “Inhibition of the repl

Affiliated with

Also associated with

Rating

β-L-2′-deoxynucleosides for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with β-L-2′-deoxynucleosides for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β-L-2′-deoxynucleosides for the treatment of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3747929